AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18386573 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint group (no needling)
Number of subjects: 26
Study 18386573 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint group
Number of subjects: 26
Study 15935319 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal model based on DEC investigation
Number of subjects: 0
Study 15935319 — intervention group
Group type: COMPARATOR
Intervention: Trained police officers
Number of subjects: 0
Study 15935319 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal model
Number of subjects: 0
Study 14746378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep loss (0, 2, 4, and 8 hours of sleep loss)
Number of subjects: 32
Study 14746378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.0 g/kg, 0.3 g/kg, 0.6 g/kg, and 0.9 g/kg)
Number of subjects: 32
Study 14746378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep loss
Number of subjects: 32
Study 14746378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 32
Study 11293914 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born to mothers with well‐controlled diabetes
Number of subjects: 57
Study 11293914 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 57
Study 11293914 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born to mothers with diabetes
Number of subjects: 57
Study 8917198 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lung wrap-around removed (attenuation coefficient matched to heart)
Number of subjects: 15
Study 8917198 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lung wrap-around present
Number of subjects: 15
Study 8917198 — intervention group
Group type: COMPARATOR
Intervention: No left lung wrap-around
Number of subjects: 15
Study 8917198 — intervention group
Group type: COMPARATOR
Intervention: Filling of the left lung (in cases without wrap-around)
Number of subjects: 15
Study 1386975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 70
Study 1386975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 70
Study 1386975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 12 mg
Number of subjects: 70
Study 6374683 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous nasal spray of beclomethasone dipropionate (200 micrograms, twice daily for 2 weeks)
Number of subjects: 38
Study 6374683 — intervention group
Group type: COMPARATOR
Intervention: Pressurized nasal spray of beclomethasone dipropionate (200 micrograms, twice daily for 2 weeks)
Number of subjects: 38
Study 31079947 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPEC4V (4:4:4:8 μg)
Number of subjects: 848
Study 31079947 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPEC4V (8:8:8:16 μg)
Number of subjects: 848
Study 31079947 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPEC4V
Number of subjects: 848
Study 31079947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 848
Study 30179727 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cocoa group (4 g/d; 220 mg flavanols)
Number of subjects: 48
Study 30179727 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-cocoa group (2 g/d; 110 mg flavanols)
Number of subjects: 48
Study 30179727 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cocoa group (1 g/d; 55 mg flavanols)
Number of subjects: 48
Study 30179727 — intervention group
Group type: EXPERIMENTAL
Intervention: All FRC-treated groups
Number of subjects: 48
Study 27307217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 0.5 μg/kg over 10 min, followed by continuous infusion of 0.1 μg/kg/h until the end of surgery)
Number of subjects: 130
Study 27307217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 130
Study 27307217 — intervention group
Group type: COMPARATOR
Intervention: Control (volume-matched normal saline)
Number of subjects: 130
Study 25017448 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' adherence ratings
Number of subjects: 0
Study 25017448 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervisors' adherence ratings
Number of subjects: 0
Study 25017448 — intervention group
Group type: EXPERIMENTAL
Intervention: TSF expert raters' adherence ratings
Number of subjects: 0
Study 25017448 — intervention group
Group type: EXPERIMENTAL
Intervention: External raters' adherence ratings
Number of subjects: 0
Study 25017448 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence ratings
Number of subjects: 0
Study 25017448 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' reliability ratings
Number of subjects: 0
Study 22854545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative visual information and parental presence
Number of subjects: 76
Study 19464208 — intervention group
Group type: EXPERIMENTAL
Intervention: Root ZX II meter reading set at '0.5'
Number of subjects: 70
Study 19464208 — intervention group
Group type: EXPERIMENTAL
Intervention: Root ZX II meter reading set at '1'
Number of subjects: 70
Study 19808266 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg/d
Number of subjects: 302
Study 19808266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 16178946 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg
Number of subjects: 150
Study 16178946 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg
Number of subjects: 150
Study 16178946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 12174922 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate 11.25 mg subcutaneous injection every three months for 2 years
Number of subjects: 589
Study 12174922 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1 and 8, q 4 weeks)
Number of subjects: 589
Study 10441862 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (0.5 mg/kg per day, adjusted to 0.25 mg/kg per day on alternate days)
Number of subjects: 50
Study 10441862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8882570 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFC) 0.9 mg/kg/day
Number of subjects: 67
Study 8882570 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PRED) 0.75 mg/kg/day
Number of subjects: 67
Study 2193556 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA) with oxybuprocain‐hydrochloride 1%
Number of subjects: 30
Study 2193556 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA) with midazolam, piritramide and vecuronium bromide
Number of subjects: 30
Study 387494 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0
Study 387494 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 31867778 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus routine care
Number of subjects: 332
Study 31867778 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 332
Study 31867778 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus routine care (intervention group)
Number of subjects: 332
Study 31867778 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of patients who had previously undergone a similar procedure
Number of subjects: 332
Study 30657179 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program, twice a week for 6 weeks
Number of subjects: 128
Study 30657179 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study 27984472 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly spinal stabilization exercises
Number of subjects: 32
Study 27984472 — intervention group
Group type: COMPARATOR
Intervention: 1-time treatment and home exercise program
Number of subjects: 32
Study 25887430 — intervention group
Group type: EXPERIMENTAL
Intervention: MediMind
Number of subjects: 126
Study 25887430 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic Training
Number of subjects: 126
Study 25887430 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study 23998244 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic dermatitis and/or allergic rhinitis
Number of subjects: 168
Study 23998244 — intervention group
Group type: EXPERIMENTAL
Intervention: 2008-2009 seasonal influenza vaccine
Number of subjects: 168
Study 21869628 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HR)
Number of subjects: 24
Study 21869628 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 24
Study 19675485 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent Cranks (IC) training
Number of subjects: 18
Study 19675485 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 18
Study 19675485 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent Cranks (IC) training followed by Normal Cranks (NC) retention test
Number of subjects: 18
Study 18065067 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery intervention combined with technical practice
Number of subjects: 48
Study 18065067 — intervention group
Group type: COMPARATOR
Intervention: Technical practice only
Number of subjects: 48
Study 15153593 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg parecoxib sodium
Number of subjects: 50
Study 15153593 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib sodium
Number of subjects: 50
Study 15153593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12069102 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of Q10 (maximum daily dose recommended)
Number of subjects: 0
Study 12069102 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of Q10 (dose-dependent increase)
Number of subjects: 0
Study 12069102 — intervention group
Group type: EXPERIMENTAL
Intervention: Q10 supplementation
Number of subjects: 0
Study 12069102 — intervention group
Group type: EXPERIMENTAL
Intervention: Q10 with minor vitamin E dose
Number of subjects: 0
Study 12069102 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vitamin E supplementation
Number of subjects: 0
Study 9665594 — intervention group
Group type: EXPERIMENTAL
Intervention: Real magnetic stimulation (40 min)
Number of subjects: 30
Study 9665594 — intervention group
Group type: COMPARATOR
Intervention: Sham magnetic stimulation (40 min)
Number of subjects: 30
Study 7481863 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin
Number of subjects: 0
Study 7481863 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus cyclophosphamide
Number of subjects: 0
Study 7481863 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (175 mg/m2 in a 3-hour infusion)
Number of subjects: 0
Study 2651015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg) twice daily for 4 weeks
Number of subjects: 56
Study 2651015 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical looking tablet) twice daily for 4 weeks
Number of subjects: 56
Study 368744 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 14
Study 368744 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol
Number of subjects: 14
Study 31455482 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 0
Study 31455482 — intervention group
Group type: COMPARATOR
Intervention: Small Group Discussion (SGD)
Number of subjects: 0
Study 28757482 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hsTnI)
Number of subjects: 1081
Study 26964166 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of shuang huanglian injection (1 mL at each point, three times a week for 2 weeks) and fire needling (once a day for 3 times)
Number of subjects: 158
Study 26964166 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of vitamin C (100 mg, three times a day) and vitamin B2 (20 mg, three times a day) and subcutaneous injection of transfer factor (2 mL, twice a week for 2 weeks)
Number of subjects: 158
Study 22899659 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Deficits Questionnaire (PDQ; range 0‐20)
Number of subjects: 120
Study 22899659 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cognitive function score (range 0‐16)
Number of subjects: 120
Study 22899659 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis controlling for various factors
Number of subjects: 120
Study 21762358 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg
Number of subjects: 984
Study 21762358 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 80 mg
Number of subjects: 984
Study 21762358 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 984
Study 21762358 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg and 80 mg
Number of subjects: 984
Study 19347979 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral carboxyaminoimidazole
Number of subjects: 186
Study 16461612 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceived seriousness of acquiring a sexually transmitted infection
Number of subjects: 376
Study 16461612 — intervention group
Group type: EXPERIMENTAL
Intervention: Having 'other' (not steady) partners in the last 6 months
Number of subjects: 376
Study 15304143 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in shared decision making (SDM) skills and risk communication materials
Number of subjects: 20
Study 15304143 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk communication intervention
Number of subjects: 20
Study 15304143 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM intervention
Number of subjects: 20
Study 15304143 — intervention group
Group type: EXPERIMENTAL
Intervention: Female doctors
Number of subjects: 20
Study 15304143 — intervention group
Group type: EXPERIMENTAL
Intervention: Time constraints
Number of subjects: 20
Study 10816230 — intervention group
Group type: EXPERIMENTAL
Intervention: External ultrasound (EUS) therapy applied at therapeutic energies
Number of subjects: 25
Study 10816230 — intervention group
Group type: COMPARATOR
Intervention: Placebo settings
Number of subjects: 25
Study 8968180 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension using sodium nitroprusside
Number of subjects: 40
Study 8968180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypotension)
Number of subjects: 40
Study 1758394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Cyclophosphamide
Number of subjects: 1
Study 1758394 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 1
Study 6122770 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg/day
Number of subjects: 28
Study 6122770 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 400 mg/day
Number of subjects: 28
Study 6122770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31126542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheongsangbangpoong-tang (CBT) 5g extract, three times a day for 8 weeks
Number of subjects: 56
Study 31126542 — intervention group
Group type: COMPARATOR
Intervention: Placebo 5g extract, three times a day for 8 weeks
Number of subjects: 56
Study 30169215 — intervention group
Group type: EXPERIMENTAL
Intervention: PPOIT (Probiotic and Peanut Oral Immunotherapy)
Number of subjects: 48
Study 30169215 — intervention group
Group type: EXPERIMENTAL
Intervention: PPOIT
Number of subjects: 48
Study 30169215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25811286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sujon New Zealand blackcurrant powder (6g/day)
Number of subjects: 13
Study 24662446 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised self‐completed study measurement instruments
Number of subjects: 20
Study 24662446 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies used by interviewees (adding notes, adding response categories, skipping an item)
Number of subjects: 20
Study 24662446 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials addressing differential logics
Number of subjects: 20
Study 24662446 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot testing validated instruments using cognitive interviews
Number of subjects: 20
Study 24662446 — intervention group
Group type: EXPERIMENTAL
Intervention: Method for participants to convey personal experiences
Number of subjects: 20
Study 22970658 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine MR 400 mg OD
Number of subjects: 363
Study 22970658 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg OD
Number of subjects: 363
Study 22970658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 19895369 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 14
Study 19895369 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 14
Study 19895369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19895369 — intervention group
Group type: COMPARATOR
Intervention: Control condition without intervention
Number of subjects: 14
Study 18070259 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory Factor Analysis (EFA) on sample of 9,856 participants
Number of subjects: 19777
Study 18070259 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory Factor Analysis (CFA) on sample of 9,921 participants
Number of subjects: 19777
Study 16214026 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) levels
Number of subjects: 0
Study 16214026 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP) levels
Number of subjects: 0
Study 16214026 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 receptor antagonist (IL-1ra) levels
Number of subjects: 0
Study 16214026 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 0
Study 11828898 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-vision lenses
Number of subjects: 71
Study 11828898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal glasses
Number of subjects: 71
Study 9873237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for infertile couples
Number of subjects: 17
Study 7669460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac before operation
Number of subjects: 90
Study 7669460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ketorolac)
Number of subjects: 90
Study 2572609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 23
Study 2572609 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 23
Study 1207761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine
Number of subjects: 15
Study 1207761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31593215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian weighted Mendelian randomization (BWMR)
Number of subjects: 0
Study 31173150 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fraction hypofractionated stereotactic radiotherapy (HSRT) with a median total dose of 30 Gy (range, 25-35 Gy)
Number of subjects: 122
Study 31173150 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fraction hypofractionated stereotactic radiotherapy (HSRT)
Number of subjects: 122
Study 28339554 — intervention group
Group type: EXPERIMENTAL
Intervention: Antazoline (up to 250 mg intravenously)
Number of subjects: 74
Study 28339554 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 74
Study 28339554 — intervention group
Group type: EXPERIMENTAL
Intervention: Antazoline
Number of subjects: 74
Study 25940675 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐05231023 (200 mg)
Number of subjects: 0
Study 25940675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25940675 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐05231023 (high-dose groups)
Number of subjects: 0
Study 23836190 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib 900 mg/m² dose bid for 7-14 days (pre-resection treatment)
Number of subjects: 42
Study 23836190 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib continuously at 900 mg/m² dose bid in phase II study
Number of subjects: 42
Study 23836190 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 42
Study 22100793 — intervention group
Group type: EXPERIMENTAL
Intervention: Less relevant questionnaire (10 items)
Number of subjects: 6447
Study 22100793 — intervention group
Group type: COMPARATOR
Intervention: Additional questionnaire length (23 or 34 items)
Number of subjects: 6447
Study 22100793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analysis across all four follow-up intervals
Number of subjects: 6447
Study 19692495 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 microg Se/d as l-selenomethionine)
Number of subjects: 100
Study 19692495 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplementation (80 microg I)
Number of subjects: 100
Study 19692495 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium + Iodine supplementation (100 microg Se + 80 microg I)
Number of subjects: 100
Study 19692495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21233084 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour e-learning programme focused on the recognition of child abuse
Number of subjects: 38
Study 21233084 — intervention group
Group type: COMPARATOR
Intervention: Control group (no e-learning programme)
Number of subjects: 38
Study 15825778 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 55
Study 15825778 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 55
Study 12066721 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H (30% blood volume withdrawn and replaced with saline)
Number of subjects: 20
Study 11477907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine
Number of subjects: 82
Study 11477907 — intervention group
Group type: COMPARATOR
Intervention: Common treatment
Number of subjects: 82